SOBI slips after Ionis lowers Tryngolza sales forecast
IONS•SOBI shares slipped around 2% after Ionis cut its 2026 Tryngolza sales forecast to $50 million from a previous range of $100 million to $110 million. Deutsche Bank cut its rating on SOBI to hold from buy.
1. Forecast cut weighs on shares
SOBI shares slipped around 2% after Ionis cut its 2026 sales forecast for Tryngolza, its drug for severe hypertriglyceridemia, to $50 million from a previous range of $100 million to $110 million. Pareto Securities analyst Filip Wiberg said Tryngolza is seen as a significant growth driver for SOBI from 2027 and beyond.
2. Rating lowered to hold
Deutsche Bank cut its rating on SOBI to hold from buy, citing the Tryngolza move. The bank said the launch weakness was a negative in an otherwise solid picture, with the business growing at a strong double-digit pace.
